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Abstract 
Introduction: Alzheimer’s disease (AD), the most common form of dementia worldwide, is a 
multifactorial disease with a still unknown etiology. Herpes simplex virus 1 (HSV-1) has long been 
suspected to be one of the factors involved in the pathogenesis of the disease. 
Areas covered: We review the literature focusing on viral characteristics of HSV-1, the 
mechanisms this virus uses to infect neural cells, its interaction with the host immune system and 
genetic background and summarizes results and research that support the hypothesis of an 
association between AD and HSV-1. The possible usefulness of virus-directed pharmaceutical 
approaches as potential treatments for AD will be discussed as well. 
Expert opinion: We highlight crucial aspects that must be addressed to clarify the possible role of 
HSV-1 in the pathogenesis of the disease, and to allow the design of new therapeutical approaches 
for AD. 
 
 
Keywords: Alzheimer’s disease, Human herpes simplex virus type-I, immunity, mild cognitive 
impairment, pharmaceutical treatments. 
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Article highlights 
• A possible role for the reactivation of HSV-1, a virus that commonly infects humans, in the 
pathogenesis of AD is suggested by a string of observations. 
• After the initial infection HSV-1 persists in latent state in trigeminal ganglia and, upon 
reactivation can reach the brain, as showed by detection of HSV-1 viral genome in brain of 
elderly people. 
• Reactivation of HSV-1 can cause neuronal damage, directly and/or by induction of 
inflammation. 
• Host immunity is critical to control viral reactivation and it is impaired in AD patients. 
• If HSV-1 infection is a risk factor for AD, antiviral treatments could be useful in the 
prevention/treatment of this disease.  
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1. Introduction 
Alzheimer’s disease (AD) is a common form of senile dementia that in 2018 affects 50 million 
individuals around the world, and that in the near future will become one of the biggest medical 
issue, at least in western countries, due to the increase of life expectancy. Thus, the World 
Alzheimer Report predicts that in 2050 a total of 152 millions of people will suffer from AD [1]. AD 
is an inflammatory neurodegenerative disease characterized by progressive decline of normal 
cognitive abilities and of intellectual impairment, with a consequent loss of working abilities and 
the incapacity to perform daily living activities [2] Importantly, an intermediate stage between AD 
and healthy aging is Mild Cognitive Impairment (MCI), defined as a subjective and objective 
decline in cognitive performance that is greater than expected for individual’s age and education 
level, but does not meet criteria for the diagnosis of dementia [3]. The brain of AD patients is 
mainly characterized by the presence of intraneuronal neurofibrillary tangles, formed by abnormal 
phosphorylated Tau protein, and extracellular senile plaques, formed by amyloid-β (Aβ), a peptide 
produced by the proteolysis of amyloid precursor protein [4]. 
The etiology of AD is still unknown: the disease is defined as multifactorial as several factors 
interacting with each other are suspected to be involved in its development. Amongst these 
factors important roles are played by genetic background, in particular the ε4 allele of the 
apolipoprotein E (ApoE) gene, infections and inflammation. 
A role for pathogens in the development and progression of AD [5] has long been suspected, and 
human spirochetes, fungi, Borrelia burgdorferi, Chlamydophila pneumomniae, Helicobacter pylori 
and human herpes simplex virus type 1 (HSV-1) have been envisioned as possible culprits. The 
possibility that HSV-1 could be involved in the pathogenesis of AD, in particular, was originally 
hypothesized by Ball in 1982, when he proposed that “reactivation [of HSV-1] travelling 
centripetally [through known anatomic nerve fiber connections into the limbic areas of the brain] 
might be the cause of the degenerative lesions typical both of Alzheimer’s Disease and of the 
normal aged human brain” [6]. After the primary infection, HSV-1 can remain latent in the nervous 
system; very rarely, its reactivation can result in an acute and often lethal form of encephalitis [7]. 
In this case, the brain area involved are the hippocampus as well as the temporal and frontal 
lobes; interestingly these are the same brain area that are affected in AD. This observation offered 
one of the first supports to the Ball hypothesis. In 1991 Jamieson and coworkers found traces of 
HSV-1 genome in brains of sporadic AD patients; importantly viral genome was present in those 
areas – hippocampus, temporal and frontal lobes – typically affected by AD [8]. The importance of 
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these results was somewhat diminished by the fact that HSV-1 genome was also detected in brains 
of non-demented elderly individuals suggesting that brain HSV-1 latent infection is a relatively 
frequent event. Interestingly, in 1997 Itzhaki and coworkers added a further piece to this scenario 
by showing that the combination of ApoE4 allele, a genetic risk factor for AD, and HSV-1 in brain, 
greatly augments the risk of developing AD [9]. Some years later the same researchers proposed 
that recurrent reactivation of latent HSV-1 in brain results in localized neuron damage through 
direct and indirect toxic effects of the virus [10]. 
To note, the HSV-1 DNA detection in AD brain varies considerably in literature, from the absence 
[11] or small proportion of positivity (2%) [12], to a higher DNA presence (35%) [13], up to almost 
totally positive AD brain samples (70-100%)[8,9]: differences in methodological sensitivity, 
reduced DNA yield extraction from fixed material with long duration of storage may be the 
reasons of these discrepancies. Another important aspect is that not only HSV-1, but also other 
herpesvirus species (i.e. HHV-6A) [14] as well as bacteria (i.e. Borrelia burgdorferi and Chlamydia 
pneumoniae) and fungi can be detected in brain tissues [15], highlighting the need to perform 
larger studies to confirm these data and to analyze the presence of other uninvestigated 
pathogens.  
Based on literature databases (up to March 2019), in this review we summarize the main findings 
and results that support the presence of a link between AD and HSV-1, link that, acting in synergy 
with other, yet unidentified factors could have a role in the onset and development of this 
neurodegenerative disease. 
 
2. Herpes simplex virus 
Herpes simplex virus (HSV) type 1 and type 2 are human neurotropic, host-adapted pathogens 
whose lifestyle is based on a long-term dual interaction with the infected host that can establish 
both lytic and latent infections [16]. These viruses establish latent infections in sensory ganglia; 
such infections can undergo reactivations that can be either asymptomatic or symptomatic. In this 
case, cold sores, keratitis, blepharitis, meningitis, encephalitis, genital infections or systemic and 
severe conditions in immune compromised patients can be observed [17]. Dissemination is very 
common in human communities owing to latent infection, periodic reactivation, and 
asymptomatic virus shedding. HSV is a highly prevalent infection worldwide: 67% of the 
population under the age of 50 was shown to be infected with HSV-1 and 11% harbors HSV-2 [18]. 
The HSV-1 infection is generally acquired during childhood, although during the past twenty years 
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in developed countries a decreased trend of seroprevalence has been observed in adolescent and 
young adults [19]. 
 
2.1 Structure of HSV-1 
The HSV-1 virion includes 4 components: the outer envelope, the tegument, the capsid and the 
core [20] (Figure 1). The envelope consists of a lipid bilayer and anchors approximately 11 viral 
glycoproteins, four of which (gB, gD, gH, and gL) are essential in allowing virus entry into cells [21]. 
The tegument is an unstructured amorphous layer that surrounds the capsid, it includes more 
than 20 proteins and is important in the regulation of viral replicative cycle [22]. The capsid is 
composed by 162 capsomeres that are organized within an icosahedral structure. The core is the 
central domain of the virus and contains the linear, double stranded, 152 kbp DNA (dsDNA) 
genome . The HSV genome can be divided into two unique sequences, designated as unique long 
(UL) and unique short (US), flanked by large repeated sequences, internal (IRL and IRS) and 
terminal (TRL and TRS). The viral genome encodes approximately 90 unique transcriptional units, 
of these at least 84 encode proteins that can perform many functions in the infected cell. 
 
2.2 Virus attachment and entry  
To initiate infection, HSV-1 binds at least three different classes of cell-surface receptor and fuses 
its envelope with the plasma membrane. The entry of HSV-1 into epithelial cells is a complex 
process [23]. Its envelope contains 11 glycoproteins that are very important in mediating the initial 
steps of viral attachment and entry into the cell as well as facilitating cell-to-cell spread of the virus 
[21]. The virus enters by fusion with the plasma membrane or via endosomes through an 
orchestrated process that requires gB, the most ubiquitous envelope glycoprotein in human 
herpesviruses, and three other essential envelope glycoproteins (gD and gH/gL), activated in a 
cascade fashion. 
Glycosaminoglycan-chains (GAGs) are expressed on the host cell; among these, heparan sulfate 
(HS) proteoglycans (HSPGs) are the primary attachment receptors for HSV gB and gC. The 
interaction of gC and gB with HS receptor is labile and is reinforced by the participation of gD in 
the process [24,25]. After the viral and the host membranes are brought into close vicinity, gD 
interacts with one or more cellular receptors [25] inducing a conformational change to the 
heterodimer gH/gL, modifying it into a form that interacts and triggers the fusogenic activity of gB 
[23]. By the interaction of gH/gL with gB, the prefusion glycoprotein shifts to a post fusion 
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conformation that is capable of forming the fusion pore. 
Fusion pore completes the fusion process; at this point the virion particles, along with the 
tegument, enter the cytoplasm. After penetration into the cytoplasm, some tegument proteins 
remain in the cytoplasm while other are transported to the nucleus or remain associated with the 
capsid that travels via microtubule network, to the nucleus [26]. The processes of transcription 
and replication of the viral genome, as well as the assembly of progeny capsids, take place within 
the nucleus.  
 
2.3 Lytic cycle 
Ones inside the nucleus, viral DNA is rapidly circularized and viral genes are expressed in a tightly 
regulated, interdependent temporal sequence. The lytic cycle of HSV-1 can be divided into three 
phases, which involve the expression of three groups of viral genes: α or Immediate Early (IE), β or 
Early (E) and γ or Late (L) [20]. IE genes are first expressed, about 2-4 hours post-infection, by the 
combined action of the tegument viral protein (VP) 16, known also as α-TIF (α-trans-inducing 
factor) with at least two cellular proteins, the octamer-binding protein (Oct-1) and the host cell 
factor 1 (HCF-1), that targets the TAATGARAT motif upstream of the IE promoters stimulating the 
transcription of five IE genes [27]. During this early stage the corresponding proteins are 
synthesized: infected-cell polypeptide (ICP)4, ICP27, ICP22, ICP0 and ICP47. ICP4, an essential viral 
protein, is a DNA binding protein that interacts with basal transcription factors, such as TATA-
binding protein (TBP), TFIIB, TFIID and TAF250 [28]. This interaction activates most E and L genes 
and represses the transcription of other IE genes [28]. ICP27, in particular, is responsible for the 
post-transcriptional modifications that control viral mRNA splicing, represses the expression of 
some IE and E proteins and induces L protein expression [29]. ICP27 also contributes to the 
decrease of cellular genes expression and is an important regulator of host cell fate [29]. ICP22 
plays an important role in replication and pathogenicity of HSV-1 since his function is crucial to 
allow the optimal expression of E and L genes, to promote the formation of functional virions 
composition, and to permit capsid nuclear egress [30]. ICP47 binds to the transport proteins TAP1 
or TAP2, preventing the transport of viral peptides to the endoplasmic reticulum [31]. ICP0 is a 
transactivator that promotes transcription of many viral and cellular genes during the lytic 
infection and is essential for latency reactivation [32]. ICP0 is a RING finger protein and exhibits 
two distinct ubiquitin ligase activities that interact with different cellular E2 ubiquitin-conjugating 
enzymes and therefore targets different cellular substrates [32]. The major mechanism of action of 
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ICP0, thus, may be the degradation of specific cellular proteins via the ubiquitin-proteasome 
pathway [32]. After IE gene transcription and expression, the E phase starts, this leads to the 
production of proteins responsible for viral DNA synthesis and packaging. Expression of E genes 
requires at least the presence of functional ICP4 and reaches a peak at 4-8 hours post-infection. 
During this phase, proteins mostly act as enzymes and are responsible for the replication of the 
viral genomes that are produced. Among them important roles are played by DNA polymerase 
(UL30/UL42 complex), thymidine kinase (TK), single-stranded DNA (ssDNA) binding protein (SSB), 
also known as ICP8, a DNA helicase-primase, and UL9 [20,21]. Finally, viral DNA replication 
stimulates the transcription of L genes that mainly consist of structural proteins of the virion, such 
as tegument and envelope proteins, and proteins responsible for the assembly of the viral particle. 
The assembly of the viral particle starts in the nucleus: a procapsid, a spherical fragile intermediate 
is formed, the DNA is then packaged and undergoes a morphological change to become a mature 
icosahedral capsid [20,21].  
 
2.4 HSV-1 infection in neuronal cells and latency establishment  
The initial site of entry within neurons is usually at the axon terminus near peripheral epithelial 
cells [33]. The entry mechanism in sensory nerves depends on the cell type and on the interaction 
of viral glycoproteins with the cellular receptors [33]. During infection of neurons, HSV-1 causes a 
biphasic remodeling of the actin cytoskeleton by first inactivating and then reactivating cofilin-1, 
resulting in F-actin assembly and disassembly during early and late stages of infection [33]. After 
the fusion, the capsid is transported retrogradely to the nucleus along the microtubules; this 
transport involves the dynein/dinactin complex [34]. Release of the viral genome in the neuronal 
nucleus results in its rapid association with histones to create a circular episomal DNA. Viral genes 
are not expressed at this stage with the exception of LAT gene which is expressed in high 
abundance [35]. The functions of LATs transcripts are not completely clear, but they have a 
fundamental role in maintaining viral latency which can silence lytic gene expression and block 
apoptosis [36]. During latency, chromatin plays an important role: in fact, the histones associated 
with the latent viral genome are often modified [35]. Experimental animal model have been used 
to show that in the trigeminal ganglia of infected mice the expression of genes IE, E and L occurs in 
the first 24-72 hours after infection, whereas in the following period their expression decreases 
and LAT transcripts accumulate: this results in the establishment of latent infection [37]. Generally 
sensory neurons do not express lytic proteins, but several stress stimuli may induce the 
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reactivation of the virus in these neurons. The assembled capside exits the nucleus through the 
inner nuclear membrane and merges with the outer nuclear membrane. Viral capsids containing 
inner tegument proteins with or without an envelope, and vesicles associated with glycoproteins 
and tegument proteins are targeted for active transport along microtubules in axons using the 
neuronal secretory pathway. The virus is then transported in anterograde manner to the area of 
primary infection where a new productive infection starts [38].  
 
3. Virus-host interaction 
3.1 HSV-1 and apoptosis  
Apoptosis, also called programmed cell death, is an important innate mechanism that eliminates 
pathogen-infected cells. This mechanism has a crucial role in limiting viral replication and 
transmission emphasizing the importance of this host-interaction process in viral pathogenesis.  
HSV has evolved in the manner to modulate apoptosis in different cell types either with anti-
apoptotic genes to promote the generation of new viral progenies or with pro-apoptotic genes to 
promote cell death to favor viral release and shedding. LAT, US3 and many other HSV-1 genes, 
including ICP4, ICP34.5, UL54, US1, US5 and US6 [39] are suspected to regulate apoptosis. The 
ability of LAT to interfere with apoptosis correlates with its ability to promote spontaneous 
reactivation [40]. LAT inhibits multiple steps in apoptotic cascades and inhibit dephosphorylation 
of pAKT levels to promote cell survival and indirectly to control caspase 3 and block apoptosis [41]. 
The two small RNAs encoded by the initial part of LAT gene are involved in the inhibition of 
caspase 8- and caspase 9-induced apoptosis [42]. The US3 is a multifunctional protein kinase that 
plays various roles in the viral life cycle by phosphorylating a number of viral substrates [43]. US3, 
can block apoptosis, as it activates antiapoptotic substrates targeted by the cellular cyclic 
adenosine monophosphate (cAMP)-dependent protein kinase [44]. Benetti and Roizman have 
demonstrated that Us3 blocks the proteolytic cleavage of caspase 3 inhibiting its activation and 
consequently the apoptotic event [45]. Many other viral proteins have a role in blocking apoptosis 
(summarized in table 1), in particular, US5 that encodes for the non-essential glycoprotein J (gJ) 
inhibits caspase 3/8 activation through Fas-mediated or granzyme B induced apoptosis [46,47].  
3.2 HSV-1 and host immunity  
Multiple innate immune pathways cooperate to form a barrier to viral infection: particular 
receptors (called pattern recognition receptors, PRRs) survey cells surface and intracellular 
compartments for specific pathogen-associated patterns (PAMPs), including viral DNA, RNA and 
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proteins. Toll like receptor-2 (TLR2) recognizes HSV-1 envelope glycoproteins (gD, gH, gL and gB), 
whereas on TLR9 and TLR3 detect respectively viral GC-rich/AT-repeated DNA regions and double 
strand RNA (dsRNA) [48]. TLR3, in particular, has an important protective role against HSV-1, as 
witnessed by the observation that patients with TLR3 dominant negative mutations are more 
susceptible to herpes simplex encephalitis [49]. 
A number of cytosolic receptors have been suggested to sense HSV-1 nucleic acid as well. Thus, 
RIG-1 and MDA-5 sense dsRNA whereas other receptors (cGAS, DNA-PK, DAI, IFI16, DDx41, DHx9, 
DHx36) are activated by viral DNA, although for many of these receptors the precise mechanism 
remains to be investigated [48]. 
After the binding of viral ligands to receptors, adaptors (such as MyD88, TRIF, MAVs, STING) are 
recruited, kinase proteins (as IKK, TBK) are activated and, after nuclear translocation of 
transcription factors (NF-Kb; IRF3; IRF7), type I IFNs (IFN-α and IFN-β) are generated; IFNs are 
crucial for the control of infection as they production induces the expression of hundreds of 
responsive genes (ISGs), among which pro-inflammatory cytokines (IL-6, IL-12, TNFα) and 
chemokines (CXCL-10, CXCL-9) that promotes viral clearance through the recruitment of 
specialized immune cells. 
The inflammasome is activated as well by HSV-1: this process is started by DNA binding to sensor 
molecules (IFI16 and NOD-like receptor family pyrin domain containing 3 or NLRP3) and results in 
the production of the pro-inflammatory cytokines IL-1β and IL-18 [50]. IFI16 (IFNγ-inducible 
protein 16), in particular, is another important player in the immune response to HSV-1. Thus, 
IFI16 binds the viral genome in the cytoplasm of the infected cell through STING/IRF3 proteins 
[51]; this leads to type 1 IFNs expression, and, through the activation of the inflammasome to IL-
1β and IL-18 release. Notably this proteins has a nuclear action as well, as in the nucleus it 
promotes heterocromatin assembly on HSV-1 DNA and silences HSV-1 expression [52]. 
Another central element of innate immunity is the complement system, whose components (in 
particular C1q e C3b) can directly bind to HSV-1. This leads to antibody (Ab)-mediated 
neutralization of the virus, inhibition of receptor binding on the surface of cells, reduction of the 
infectivity, and lysis of infected cells. The classical pathway of the complement is also triggered in 
an antibody-independent manner when C1 directly binds to virions or to infected cells. The 
complement system is also essential in the regulation of adaptive responses by enhancing T and B 
lymphocytes-mediated responses. 
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The production of cytokines and chemokines induces adaptive antigen-specific cell response. Viral 
antigens, bound to MHC-I and presented by antigen presenting cells (APC), are recognized by 
CD8+T lymphocytes, this results in the activation of their effector mechanisms and the 
establishment and maintenance of memory T cells. Granzymes and perforins induce the lysis of 
infected cells; IFN-γ production by activated T lymphocytes enhances the processing of viral 
peptides that will be presented by MHC, thus expanding the potency of cells-mediated immune 
responses. 
Overall, if the innate immunity system mainly controls the initial phase of HSV-1 replication, cell-
mediated adaptive immunity play a major role in preventing reactivation from latency and limiting 
of viral spread [53]. 
A novel population of T cells known as tissue-resident memory CD8+ (TRM) T cells has been 
recently described, these cells are critical for peripheral immune surveillance and protection 
against viral infection [54]. Following a primary HSV-1 infection, CD8+TRM cells are generated and 
retained for long time in non-lymphoid tissue, including ganglia and mucosa [55]. CD8+TRM survey 
latently infected niches, if infected cells are detected, IFN-γ and granzyme B will promptly be 
produced. The regulation mechanisms for TRM cell during viral reactivation in central nervous 
system (CNS) remain unclear but it is conceivable that vaccines boosting the resident CD8+TRM 
cells could be a viable option for protection against HSV-1 infection and/or reactivation. 
CD4+T cells are critically important for the prevention of HSV genital infection [53] and they are 
responsible for herpes stromal keratitis, following the production of Th1 cytokines. Notably, these 
cells are also present in sensory ganglia and spinal cord, where they mediate clearance of HSV-1 
from neural tissue and persist for a long time after infection. 
The Ab response to HSV-1 infection is broad, polyclonal and is mainly directed towards envelope 
glycoproteins as well as toward tegument and capsid proteins [56]. During infection gD and gB are 
the most important viral proteins in stimulating the production of IgGs; these Ab will then prevent 
the interaction between HSV-1 and its cell receptors, neutralizing viral infectivity. The role of 
humoral immunity in protection against HSV-1 infection is however still controversial [57]: 
naturally induced Abs are not able to protect from viral reactivation and to completely avoid virus 
transmission. This is at least partially the consequence of the ability of the virus to develop 
immune evasion strategies to inhibit neutralizing Ab response, including transmission through the 
cell-to-cell spread that protects the virus from immune surveillance. 
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Interestingly, HSV-1-specific cell-mediated immune responses can be detected in HSV-1 
seronegative individuals [58]; this could be a consequence of HSV-1 cross-reactivity with other 
herpesviruses, including varicella zoster virus (VZV): these two viruses in fact present homologies 
in numerous genes; immunity related to VZV infection or vaccination could thus modulate HSV-1 
or HSV-2 infection and vice versa [59]. 
Notably attempts to obtain an effective vaccines based on induction of Ab response by gB/gD 
envelope glycoproteins, showed only limited efficacy in humans, suggesting that a more complete 
protection against HSV-1 infection might be obtained upon stimulation of high titers of 
neutralizing Abs and, likely, by designing vaccines that will preferentially stimulate HSV-1-specific 
cell -mediated immunity (in particular tissue resident memory T-cells [60]. 
 
3.3 Evasion from host immunity 
HSV-1 has evolved several mechanisms to counteract the host immune response, allowing its 
persistence in infected hosts humans (reviewed in 48 and 61 and summarized in Table 2). Usually 
the host uses the xenophagy - i.e. the autophagic degradation of intracellular pathogens - to block 
HSV-1 infection [62]. HSV-1 xenophagy is stimulated by type 1 IFNs and is mediated by antiviral 
proteins, including the double stranded RNA-dependent protein kinase R (PKR). PKR is activated 
upon binding a double-stranded RNA; this precludes protein synthesis in virus-infected cells by 
phosphorylation of the α subunit of eukaryotic initiation factor 2 (eIF-2α). HSV-1 produces two 
different proteins to evade this defense mechanism: US11 and ICP34.5. In particular, US11 directly 
binds to PKR, blocking its phosphorylation and inhibiting its activity, whereas ICP34.5 recruits 
phosphatase proteins of the host to phosphorylate eIF2α with consequent translation blockage. 
Both these two viral proteins are required for full resistance to type 1 IFN-mediated immune 
response, as both inhibit autophagic degradation of HSV-1 proteins [63]. To note, ICP34.5 is able 
to inhibit autophagy also in an alternative way, binding the essential autophagy protein beclin 1. 
LAT also can interfere with the type 1 IFN pathway, as it was demonstrated in animal models that 
this transcript regulates the expression of IFN in neurons [64]. Another HSV-1 key protein is the 
US3 tegument protein. US3 dampens the IFN-β signaling and reduces IFN–γ production by 
cytotoxic T lymphocytes, protecting the infected cells from lysis [65]. US3 can also modulate TLR 
responses, inhibiting the TLR2 and TLR3 signaling, and, in association with gB, interfering with the 
activity of natural killer cells, by inhibiting CD1d antigen presentation and their consequent 
activation [66].  
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
Finally, HSV-1 can also evade the complement-dependent host immune response by binding the 
viral Fc receptor (vFcR) to the Fc end of IgGs; this results in the suppression of complement-
dependent neutralization and the survival of infected cells. 
 
3.4 Control of HSV-1 reactivation 
Normally the nervous system activates effective innate and adaptive immune responses to contain 
HSV-1 infection [67]. In particular, upon HSV-1 infection human microglia cells produce a number 
of pro-inflammatory cytokines and chemokines [68], with a concomitant activation of lymphocytes 
to control viral replication [69]. Therefore, a delicate balance between host surveillance and viral 
immune evasion mechanisms drives HSV-1 into latency. The virological mechanisms, related to 
latency and reactivation, have been extensively investigated [16,69]. The absence of viral product 
during latency in neurons lead to hypothesize that cellular factors act as “trigger” for HSV-1 
reactivation, but we have only a partial knowledge of these factors. Reactivation can be induced in 
humans by environmental stress (UV radiation, fever, fatigue, hormonal change, cranial trauma, 
immunesuppression) and by other stimuli (i.e. NGF deprvation or histone deacetilase inhibition), 
as observed in cultured neurons or using animal models [16]. It is important to underline that 
these experimental approaches are often imperfect and they don’t completely represent the 
natural occurring reactivation in humans, where probably other characteristics (related to cell 
type, species, or viral strain) can determine the results of this complex mechanism. Other 
concomitant infections, as i.e. with human Cytomegalovirus (CMV) [70], can be considered as well 
important factors inducing HSV-1 reactivation. The current understanding of the factors regulating 
latency reactivation is limited yet and much more knowledge should be gained before to have a 
clearer picture of viral reactivation process. 
In vivo studies in the murine model showed that HSV-1-infection of trigeminal ganglia results in 
the expression of major histocompatibility complex (MHC) class II antigens and triggers the 
production of pro-inflammatory and neuroinflammatory cytokines and proteins [71]. Interestingly, 
in the case of encephalitis, disease severity and the disruption of the blood-brain barrier are the 
consequence of the pro-inflammatory response to the virus [72], and immune markers of 
lymphocyte activation remain increased in cerebrospinal fluid for many months after the 
resolution of infection [73]. 
It is believed that reactivation can be controlled mainly by an efficient generation of CD8+ and to a 
lesser extent of CD4+T lymphocytes. Most of the CD8+T cells infiltrating trigeminal ganglia (TG) are 
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activated and secrete IFN-γ or TNF-α, but only few also express granzyme B. IFN-γ inhibits the 
expression of ICP0, a potent transactivator of viral genes that promote lytic cycle and granzyme B 
can degrade the IE protein ICP4, inhibiting viral replication in the absence of neuronal apoptosis 
[74].  
Induced regulatory T cells (iTreg) were recently indicated to be an HSV-1 “latency switch” through 
the regulation of HSV-1 specific -CD8+T cell. Thus, after acute primary infection, iTregs increase, 
this facilitates HSV-1 latency by suppressing cytotoxic response. Environmental stresses, on the 
other hand, result in an increase of iTreg cells and modulate glucocorticoid expression; this results 
in a decrease of CD8+T cell surveillance and HSV-1 reactivation [75]. Although further study are 
needed to better understand the fine mechanism of their interaction with CD8+T cells, 
manipulation of iTreg-cell-based could help in the prevention of damages derived from HSV-1 
reactivation. 
Most of HSV-1 infected individuals are “asymptomatic”, as viral reactivation is infrequent. In 
addition, only a minority of “symptomatic” subjects shows evident symptoms and recurrence of 
disease. The complex mechanisms that lead asymptomatic subjects to be “naturally protected” 
from clinical disease, are not completely known, and seem to derive from variations in the number 
and nature of the HSV-1 antigens (mainly gB and gD) that are targeted by cell immunity [76]. The 
identification of these “protective” epitopes, that characterize naturally protected individuals, 
represents a remarkable advance in the understanding of the immunological control of HSV-1 
reactivation. Studies on whole profiles of “protective” or “pathogenic” HSV-1 antigens will help to 
develop new effective vaccine stra egies. Moreover, the phenotypical and functional 
characterization of the viral epitopes that are presented to T lymphocytes in relation to different 
HSV-1 clinical manifestation will further clarify the nature of the relationship between host 
immunity and pathogenesis. 
 
4 The interplay between HSV-1 and AD 
4.1 HSV-1 specific immunity in AD patients  
Evidences of microglia-mediated inflammation in AD brain have been reported by many authors. 
Thus, in AD brains, TLR expression is upregulated and pro-inflammatory cytokines and chemokines 
are produced [77,78]. Although it is hard to know if these features are a consequence of the 
disease or contribute to its pathogenesis, a realistic hypothesis is that a vicious cycle is created, 
where IFN-γ-producing T cells infiltrate the CNS [79], driving Aβ deposition/accumulation, while Aβ 
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activates glial cells to produce others inflammatory mediators, leading to chronic process of 
neuronal dysfunction and cellular death. 
In a recent work, De Chiara and co-authors have established a mouse model of HSV-1 infection 
where they show AD-like phenotype in animal brains after multiple viral reactivation after thermal 
stress. In this work they demonstrated that the accumulation of Aβ, hyperphosphorilated Tau and 
cognitive deficit was proportional to the numbers of HSV reactivations [80]. HSV-1 repeated 
reactivations from latency are likely to have a significant impact on the pathogenesis of AD [6] as 
such reactivations would concur to neuronal damage directly, via viral action and indirectly as a 
consequence of the upregulation of neuroinflammation. Several authors investigated the possible 
role of HSV-1 in the pathogenesis of AD by analyzing HSV-1-specific humoral immunity [reviewed 
in 81]. After a first important prospective study correlating the presence of HSV-1 specific IgM (an 
indicator of episodes of HSV-1 reactivation) with risk to develop AD [82], other authors observed 
that elevated HSV-1-IgG Ab titers are significantly more frequent in patients compared to age-
matched healthy controls [83]. A positive correlation between HSV-1-specific IgG titers and the 
cortical volumes of brain regions typically affected in AD was also described in mild AD patients 
[84]; this data indicate a possible protective role of HSV-1-specific humoral immunity in the early 
phase of AD. Notably, this effect is specific for HSV-1, as no relations were observed between 
CMV- and human herpesvirus 6 (HHV-6)-specific Abs and either magnetic resonance imaging (MRI) 
or clinical parameters in AD patients [84,85]. 
At least two other experimental observations favor the hypothesis that HSV-1-specific Abs have a 
protective effect against AD development. Thus: 1) AD incidence increases with age, possibly as a 
consequence the natural decline of the potency of immune responses seen in senility [86]; 2) age-
dependent BBB injuries, although detected in normal brain, are more pronounced in MCI subjects 
compared to age-matched normal subjects [87]: consequently the high concentration of HSV-1 
specific Ab could limit viral reactivation in that brain regions where the BBB is disrupted.  
The efficacy of humoral responses is also modulated by Ab avidity, that is the relative strength 
with which Abs bind antigens. A significantly increase of the HSV-1 IgG avidity index was described 
in MCI compared to AD individuals [88]; additionally another study showed that HSV-1-specific Ab 
avidity was significantly higher at baseline in MCI-non-converters compared to those MCI who did 
develop AD [89]. Notably, in that study, a positive correlation was observed between avidity of 
Abs and cortical volumes (MRI analyses). However, other experiments are needed to better 
understand the role of Ab avidity in neurodegeneration. 
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
The biological properties of Abs are different in different IgG subclasses. A comparative analysis of 
the distribution of the four HSV-1-specific IgG subclasses showed a significantly increased 
frequency of HSV-1-specific IgG3, the subclass with the strongest complement activation ability, in 
MCI compared to AD and healthy controls (HC) [90,91]. It is also known that at least three HSV-1 
envelope glycoproteins regulate complement system and are able to prevent or reduce 
phagocytosis-mediated virus neutralization: the heterodimer gE-gI binds Fc portion of Ab molecule 
and function as IgG Fc receptor (vFcγR) [92]. Moreover gC directly binds complement components 
(C3 and C5), inhibiting complement activation and virus neutralization as well as complement 
mediated lysis of infected cells [93]. It is important to note that HSV-1 specific IgG3 Abs also have 
the highest neutralizing capacity of all Ab subclasses [94]. The development of an IgG3 response in 
MCI patients could thus be interpreted as an attempt to prevent HSV-1 reactivation. Finally, the 
protective effect of Abs in the early phase of AD could be also due to CD4+T lymphocytes 
functional impairments: a recent paper showed that Ab access to neuronal tissues is controlled by 
local secretion of IFN-γ from CD4+ memory T cells in a mouse model of genital HSV infection [95]. 
To note, other viruses are suggested to be involved in cognitive impairment, as Epstein Barr virus 
(EBV) and CMV [96]: new researches are surely needed to better understand if one or several 
microbes are involved in AD. 
 
4.2 HSV-1, amyloid beta and calcium  
One of the major hallmark of AD is th  presence of cortical senile plaques in the brain of affected 
patients [4]. The major component of these plaques is Aβ, that derives from the cleavage of the 
ubiquitous membrane protein amyloid precursor protein (APP) that in central nervous system 
(CNS) is expressed by neurons, astrocytes and microglia in 8 different isoforms. Its primary 
physiological function is not known, but it seems to be involved in neuronal survival, synaptic 
plasticity and cell adhesion [97]. In healthy individuals APP cleavage is mainly mediated by β-
secretase, while in AD patients γ pathway is more enhanced resulting in overproduction of Aβ, in 
particular its fragments 1-40 and 1-42, which are derived from the cleavage of precursor protein 
(APP) by β- (BACE-1) and γ-secretases. A direct relation between Aβ and HSV-1 was demonstrated 
in an vitro study showing that HSV-1 infection of human neuroblastoma cells reduces APP levels 
and increases the APP 55 KDa C-terminal fragment. Moreover, HSV-1-infected human neuronal 
and glia cells were shown to be characterized by an increase of BACE-1 and γ-secretases, leading a 
concomitant intracellular increase of Aβ 1-40 and 1-42 [98]. The brain accumulation of Aβ 1-42 
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was then confirmed by studies performed in HSV-1 infected BALB/c mice [98] as well as in HSV-1 
infected human and rat neuronal cells [99]. Data in rat cortical cells indicated that HSV-1 plays a 
role in the dualism between Ca2+ and Aβ, since the Ca2+ signalling attendant to viral attachment 
and entry induce modifications in APP that lead to its cleavage and the consequent formation of 
Aβ 1-42 accumulation [100]. These findings are particularly interesting as AD mice are 
characterized by elevated levels of Ca2+ in neurons [101], and genes involved in calcium signaling 
are deregulated in neurons of AD brains [102]. Furthermore, the link among HSV infection and AD 
amyloid plaques formation are associated also to the homology between the internal amino acid 
sequence of HSV-1 glycoprotein B (gB) and the carboxyl-terminal region of Aβ; therefore the 
intracellular processing of gB in neurons can lead to the generation of amyloid fragments that 
accelerates in vitro Aβ aggregation [103]. Moreover it was found that the Us11 HSV-1 protein 
ligates a microtubule-binding protein involved in APP trafficking [104], possibly altering its cellular 
distribution [105]. 
The co-localization of HSV-1 DNA and amyloid plaques in AD patients’ brain, besides being a strong 
evidence of a possible relation between HSV-1 and AD, supports the idea that Aβ could have an 
antimicrobial role and could be secreted to protect neurons from injuries [106]. In the case of HSV-
1, in particular, in vitro and animal studies demonstrated that repeated viral reactivations can 
result in APP processing and accumulation of Aβ and other APP fragments, although a direct effect 
of HSV-1 on Aβ accumulation remains to be confirmed in humans in vivo. Aβ anti-infective activity 
has been recently showed, even if its accumulation as oligomer results neurotoxic and can cause 
the destruction of brain structure and functionality [107]. 
 
4.3 HSV-1 and tau protein  
Another hallmark of AD pathology is the hyperphosphorylation of tau protein. The main function 
of this protein is to stabilize microtubules, a process regulated by its phosphorylation. The normal 
level of tau phosphorylation is a consequence of dynamic regulation of tau kinases and tau 
phosphatases. 
In AD, the hyperphosphorylated tau is aggregating in paired helical filaments (PHF) and 
neurofibrillary tangles (NFT) and can no longer perform this role. It has been proposed that this 
fact induces microtubules disintegrations dismantling cytoskeleton and thus neuronal transport 
[108]. This may first affect communications between neurons and finally lead to cell death [109]. 
Thus, HSV-1 infection causes an increase of hyperphosphorylated tau protein in murine cells [110], 
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and in neuroblastoma cells [111]. Wozniak and co-workers have demonstrated that HSV-1 
phosphorylates several sites of tau by inducing over-expression of two enzymes: GSK3β and PKA 
which are involved in protein phosphorylation [112]. To note, treatment of neuronal cells with 
antiviral drugs prior to HSV-1 infection prevents tau protein hyperphosphorylation [110]. 
 
4.4 HSV-1 and autophagy 
Autophagy is the physiological mechanism used by cells to disassemble and degrade unnecessary 
or dysfunctional components. AD is associated with a deregulation of such mechanism; this results 
in a decreased clearance of Aβ-containing autophagic vacuoles, and Aβ accumulation [113]. An in 
vitro study on human neuron cells demonstrated that HSV-1 directly impairs autophagy, increasing 
the intracellular accumulation of autophagosomes [114] and reducing Aβ autophagic degradation 
[115]. 
 
4.5 HSV-1 and oxidative stress 
The reciprocal balance between free radicals and antioxidants is altered as well in AD, where 
oxidative stress with a consequent damage to cellular molecules is present. Thus, DNA, RNA and 
proteins that are damaged as a result of oxidative stress are observed in the AD brain [116]; of 
note, oxidative stress is one of the main culprits for neuroinflammation and neurodegeneration. In 
vivo studies have proven that HSV-1 can cause oxidative stress and neuronal damage in rabbits 
[117] as well as in mice [118]; these findings were confirmed in human neuronal cells, where 
oxidative stress was shown to also result in intracellular accumulation of Aβ [119]. Notably, HSV-1 
can induce oxidative stress via mitochondrial damage, another cellular alteration seen in AD [120], 
can interfere with axonal transport of mitochondria in rat neurons in vitro [121] and can induce 
the degradation of mitochondrial DNA and mRNA in cell lines [122]. 
 
4.6 HSV-1 and host genetics 
The major AD-associated genetic risk factor is ApoE [123]. ApoE codes for ApoE protein, a fat-
binding 299 amino acid glycoprotein component of lipoproteins that plays a fundamental role in 
the maintenance and homeostasis of neurons. Three different isoforms of ApoE exist, and each of 
them differs in the ability to accomplish these critical tasks. In brain tissues, ApoE is produced by 
astrocytes and microglial cells, and is involved in different pathways, including lipid transport, lipid 
metabolism regulation, synaptic plasticity, cell signaling and neuroinflammation. Interestingly, 
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ApoE2 and ApoE3 isoforms are very effective in maintaining and repairing neuronal cells, whereas 
ApoE4 works less efficiently. Several studies showed that ApoE4 is the major known genetic risk 
factor for AD [reviewed in 123]. Although the exact mode of ApoE4 action in AD is unknown, 
higher HSV-1 viral titers and an increased expression of HSV-1 IE genes were detected in brains of 
cognitive deficits-affected mice carrying ApoE4 genotype [124]. 
A working hypothesis tying together AD, ApoE4 and HSV-1 is that ApoE4 competes with HSV-1 for 
attachment to the viral entry receptors HPSGs less effectively than ApoE3 and ApoE2 [125]. 
Other susceptibility genes for AD were identified in genome-wide association studies (GWAS); 
these include phosphatidylinositol binding clathrin assembly protein (PICALM) and nectin 2 (NC-2). 
Both these genes produce proteins that are associated with HSV-1 lifecycle: in particular PICALM is 
involved in the viral exit from the nucleus [126], whereas NC-2 codes for the HVEb adhesion 
molecule, one of the receptors for the entrance of HSV-1 into host cells [127]. 
Another group of susceptibility genes for AD are genes involved in the host immune response 
against infection. In particular: 1) clusterin inhibits the formation of the membrane attack complex 
(MAC), usually activated by infection, by interacting with several of its components [128]; 2) 
complement receptor 1 (CR1) binds complement C3 components, blocking the complement 
pathway and preventing the formation of MAC [129]. Interestingly, the HSV-1 glycoprotein C is a 
CR1 mimics and it binds the complement C3 components, turning off the complement pathway. 
Another gene involved in AD development is cholesterol 25-hydroxylase (CH25H). This protein 
regulates lipid metabolism, and is increased in the temporal cortex and the hippocampus of AD 
patients; notably high levels of Aβ deposits were observed to be associated with specific single 
nucleotide polymorphisms (SNPs) of the CH25C gene [130]. CH25H is an interferon-stimulated 
gene involved in the host immune response against viruses, HSV-1 included. In fact, CH25H 
interacts with 25-hydroxycholesterol (25OHC), a protein that prevents HSV-1 infection by blocking 
the virus-cell fusion [131]. Moreover it was demonstrated that chronic upregulation of 25OHC due 
to infections causes the accumulation of non-soluble cholesteryl esters in the brain, leading the 
cerebral vessel atherosclerosis with vascular occlusion, which contributes to AD pathology [132].  
Other results showed an association between IFN-ʎ pathway genes SNPs and AD. IFN-ʎ, includes 
four structurally related IFN-ʎ molecules (ʎ1, ʎ2, ʎ3 and ʎ4) endowed with potent antiviral 
activities. Interestingly, specific SNPs on IFNL3 and on IRF7, a fundamental transcriptional 
regulator of IFN-dependent immune responses, are associated with HSV-1 antibody titers in AD 
and MCI patients [133]. A very recent study showed that G78R, a particular variant of the paired 
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Immunoglobulin-like type 2 receptor alpha (PILRA) a negative regulator of inflammation in myeloid 
cells, is protective against AD [134]. HSV-1 uses PILRA as an entry receptor [135], and G78R down 
regulates the ability of PILRA to bind endogenous and exogenous ligands, HSV-1 included. Finally, 
because several IL-10 SNPs were suggested to be a risk factor for AD [136], and because IL-10 plays 
an important role in HSV-1 reactivation [137], it cannot be excluded that SNPs interfering with IL-
10 production, modulate HSV-1 reactivation. 
 
5. Pharmaceutical treatment: HSV-1 and Alzheimer’s Disease 
If HSV-1 is a risk factor for AD, the use of antivirals should be considered in this disease, especially 
when one considers that current AD therapies are only marginally efficacious [138]. Thus, 
cholinesterase inhibitors and memantine are the only FDA-approved medications for AD but their 
effect is extremely limited as they do not alter the course of the disease [138,139]. In vitro studies 
in which anti-HSV-1 antiviral agents, including acyclovir, penciclovir, and foscarnet were analyzed 
showed that these drugs reduce HSV-1 particles as well as Aβ and P-tau accumulation [140]. 
Notably, a recent retrospective study performed in a large Taiwanese cohort [141] suggested that 
HSV infection is associated with an increased risk of dementia and that this risk decreased after 
treatment with anti-herpetic drugs. Two other articles studied the possible relation between 
dementia and reactivation in older age of another herpetic virus, the varicella zoster virus (VZV), 
reporting an increased risk of cognitive decline after herpes zoster ophthalmicus (HZO) [142] and a 
decrease in incidence of dementia in HZO subjects treated with anti-herpetic antiviral [143]. The 
use of antivirals, notably, could down modulate CNS inflammation, reducing the production of 
pro-inflammatory molecules, Aβ and hyperphosphorylated tau proteins. Early combination of 
neuroprotective and anti-inflammatory agents may represent an efficacious approach to AD. 
Natural products, and more specifically polyphenols, have been reported as promising antiviral 
and agents for treatment of neurodegenerative disease [144]. Phytochemicals including 
flavonoids, alkaloids, terpenoids and phenols are of considerable interest for the treatment of such 
diseases [144]. Flavonoids are naturally occurring, biologically active, and therapeutically effective 
polyphenols endowed with antiviral, anti-allergic, anti-inflammatory, antitumoral, and antioxidant 
activities [145]. They can cross the BBB and may exhibit neuropharmacological activities, 
influencing the protein function and gene expression. Genistein is phytoestrogen in soybean and 
proficiently mimics the pharmacological functions of estrogen. It can act as estrogen receptors 
(ERs) agonist, and could reduce Aβ-induced toxicity [146]. Daidzein, another flavonoid, binds ERs 
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in the brain and, because of its structural similarity with estrogen, it acts as a neuroprotective 
agent antagonizing the action of estrogens [146]. Luteolin has anti-inflammatory and anti-
oxidative properties, and its protective effect on the hippocampus structure and learning flaws has 
been studied in a AD rat model [147]. Apigenin and acacetin could inhibit the activation of pro-
inflammatory cytokines and nitric oxide (NO) production, protecting AD neurons from 
inflammatory-induced stress [148]. Epigallocatechin gallate (EGCG) acts as a potent anti-oxidant 
agent and prevents the hippocampal neuronal cell death [149]. Cyanidin-3-glucoside (C3G) is a 
naturally occurring anthocyanin. Results obtained in SK-N-SH neuroblastoma cell line showed that 
C3G reduces Aβ 1-42 accumulation, H2O2-induced neurotoxicity, ROS production and dampens 
the Aβ-induced expression of ER stress proteins [150]. Pelargonidin (PEL), an anthocyanin, crosses 
the BBB, inhibits inducible nitric oxide synthase (iNOS), a pivotal driver of oxidative stress, as well 
as NO production and NF-κB expression [151]. All these products can modulate molecular 
pathways that are altered by HSV infection.  
Other natural products with an antiviral action and the ability of inducing protection from 
neurodegeneration are Resveratrol (RSV) and Quercetin, which are known activators of Sirt1 
(NAD+-dependent deacetylase sirtuin 1) and AMPK (5’AMP-activated protein kinase) [151-154]. 
Several studies have demonstrated that, during neuronal infection, HSV-1 modulates the 
AMPK/Sirt1 axis. Particularly, AMPK is down-regulated during early infection; on the other hand, 
the levels of Sirt1 increase, suggesting that the AMPK/Sirt1 axis is differentially modulated by the 
virus during infection [155]. RSV and Quercetin activate the AMPK/Sirt1 axis and induce 
neuroprotective and antiviral effects in HSV-1-infected neuronal cultures [156]. Other studies have 
demonstrated the capacity of RSV and Quercetin to delay axonal degeneration after injury [155], 
to block accumulation of Aβ peptide in vitro [156], to reduce BACE-1, which mediates the APP 
cleavage [155], and to provide protection from brain ischemia in both adult and neonatal rodents 
[157,158]. Palmitoylethanolamide (PEA), an endogenous lipid mediator is also endowed with anti-
inflammatory and neuroprotective effects [159]. A murine model showed that PEA counteracted 
the activation and inflammation seen in AD-like mouse astrocytes and promoted neuronal viability 
[160]. Table 3 summarizes the drugs discussed in this paragraph. 
 
6. Conclusions 
Reports investigating a possible role for HSV-1 in the pathogenesis of AD pathogenesis are 
accumulating and are making increasingly clear that HSV-1 infection is a very likely co-factor of this 
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neurodegenerative disease (see Figure 2). Notably, this does not preclude a role for other 
microorganisms that, acting through peripheral infection and/or inducing the reactivation of latent 
viruses, can contribute to chronic inflammation in the brain and the consequent neuronal damage. 
The smoking gun is missing and much work remains to be performed to clarify the possible 
mechanisms of viral contribution to AD neurodegeneration, and to verify whether the use of anti-
virals could be useful in preventing AD and/or reducing its progression. It is nevertheless 
important to remember the story of Barry J. Marshall and J. Robin Warren who won the 2005 
Nobel prize for the discovery of the bacterium Helicobacter pylori and its role in gastritis and 
peptic ulcer disease. The hypothesis was first published in 1984 [161], it took these scientists a 
long time for their discoveries to be accepted by the scientific community. Antibiotic drugs are 
nowadays current treatment in gastric and peptic ulcers.  
 
7. Expert opinion 
The discouraging results obtained in clinical trials for AD, trials that mainly focus on Aβ 
accumulation and its elimination, suggest the need for alternate strategies to fight this cruel and 
devastating disease. Although a general erroneous idea often identifies viruses with acute damage 
only, many examples (e.g. HIV, measles, JCV) exist in human pathology indicating that viruses can 
persist in the body throughout life and can result in diseases many years after the primary 
infection. 
A large number of evidences suggests a possible link between HSV-1 and AD, and results obtained 
in vitro and in animal models indicate that HSV-1 infection can result in anatomical and cellular 
abnormalities that resemble those seen in AD. 
However, several important points must be underlined: 
1) HSV-1 is a very common and widespread virus; fortunately nevertheless the majority of HSV-1-
infected individuals does not developed AD. HSV-1, thus, can’t be the only causative factor of AD, 
but it is a risk factor that, among others, as genetics, inflammatory status, or other infections, can 
favor the onset and development of the disease. The main question within this hypothesis is if AD 
can develop in the absence of HSV-1 i.e. whether the presence of HSV-1 is a necessary and 
mandatory factor in AD pathogenesis. As other pathogens have been detected in brain of AD 
subjects and the disease can also develop in HSV-1 seronegative subjects, in future it will be 
interesting to analyze the entire microbiome. 
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2) If HSV-1 is one possible risk factor for AD, as the distribution of HSV-1 seroprevalence with age 
is changing, with an increased number of younger subjects susceptible to HSV infection compared 
to twenty years ago, we cannot exclude that this epidemiological change can have future effect on 
the risk of dementia. Although the outcome of infection is determined by several combined 
factors (i.e. genetic of the host, biology of virus, other environmental agents), to better 
understand this aspect it will be important to perform larger epidemiological studies and to 
monitor in the next years the possible change of HSV-1-associated dementia risk. 
  
3) The presence of viral DNA in the human brain of at least a part of elderly people has been 
repeatedly shown in autoptic analyses, but the frequency and effects of viral reactivation in the 
CNS is not known and is extremely difficult to investigate. As of today it is impossible to measure 
HSV-1 reactivation in brain in vivo, thus no final evidences linking HSV-1 reactivation with AD 
development can be drown. Analyses performed on CSF are an acceptable proxy of what goes in 
CNS, but it is unethical to think of performing repeated lumbar punctures in elderly people for 
research purposes, and no peripheral biomarkers of asymptomatic viral reactivation in the CNS 
have been identified. The development of probes specific for viral reactivation that could be used 
for imaging techniques and/or the identification of novel peripheral biomarkers, including 
pathology-specific microRNA could be an interesting way to allow noninvasive longitudinal 
monitoring of viral replication in brain. 
 
4) If HSV-1 reactivation is indeed linked to the development of AD, then antiviral drugs should be 
used for its prevention. But, whom should we treat? All HSV-1 seropositive subjects or, rather only 
those HSV-1 infected individuals who are characterized by an unfavorable genetic or immune 
background or in whom a familiarity for AD is known? And when should therapy be started: at the 
first symptoms of cognitive decline or should we consider the possibility of a life-long therapy?  
An intense effort to develop basic translational and clinical research needs to be envisioned to try 
and find a cure for AD, a disease whose prevalence is constantly increasing and for which no 
therapies are currently available. 
 
The idea that HSV-1 infection is associated with/responsible for Alzheimer’s disease has been 
investigated starting from the mid 80’s; this hypothesis has gained strength and has recently been 
supported by a string of experimental and clinical results. Many hints, thou, do not add up to a 
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fully convincing proof: the smoking gun is still missing. Data stemming from a long term follow-up 
study of patients showed that episodic memory impairment is associated with HSV-1 infection, 
especially among ApoE4 carriers [162]; this leads to the design of a pilot study based on the use of 
valaciclovir (VALZ-Pilot, NCT02997982), an antiviral, in AD patients and MCI individuals. Results of 
this clinical trial, now in Phase II, should help clarifying whether antivirals can modulate the 
progression of cognitive decline. Bigger trials performed in larger cohorts that include different 
ethnic groups and take into account the variety of environmental and genetic factors suspected to 
be involved in the pathogenesis of AD will nevertheless be needed to definitely verify whether 
antiviral drugs can have a preventative and/or therapeutic effect in AD [see also ref.]. 
The unequivocal identification and characterization of those HSV-1 epitopes that elicit immune 
response in Alzheimer’s patients, in HSV-1-infected asymptomatic individuals and in HSV-1-
exposed uninfected individuals, will be extremely useful in designing efficient vaccines. 
Finally, as it is known that HSV-1 can persist in enteric neurons as well, it will be interesting to 
study the effect of viral reactivation in this compartment, and to analyze if interventions aimed at 
modifying the microbioma could have a beneficial effects in AD secondary to the prevention of 
HSV-1 reactivation in the gastro enteric tract. 
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Figure Legend 
Figure 1: A schematic representation of the HSV-1 structure with lipid membrane envelope with 
viral surface glycoproteins, tegument layer containing viral proteins, icosahedral capsid shell and 
linear double-stranded DNA, is shown.  
Figure 2: HSV-1 lytic infection in the epithelial cells, the process that the virus follows to infect the 
sensory ganglion, is shown. Retrograde transport from the sensory nerve terminus to the neuronal 
cell body is also shown. Factors disrupting the homeostasis that maintains the latency state results 
in HSV-1 reactivation; HSV-1 lytic genes in particular are reactivated. Note that sensory ganglion 
projects two processes: one in the epithelial tissue, the other in the brain. Newly replicated virions 
traffic back by anterograde axonal transport mechanisms, to re-establish infection at epithelial 
tissues or brain. HSV-1 enters the brains of elderly people as their immune system declines with 
age could contribute to the development of AD. 
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Table 1: Summary of principal HSV-1 gene products with anti-apoptotic function.  
 
 
 
  
 Genes product Role Effects References
LA
TE
N
CY
 LAT 
(Latency-
associated 
transcript) 
Enhances the establishment of 
latency 
Protect the host cells from 
apoptosis 
Inhibits apoptosis blocking GrB 
Modulates Bad-Bax [163] 
IM
M
ED
IA
TE
 E
AR
LY
 
 
ICP4 
 
 
Regulates the gene expression 
cascade which controls viral 
infection. 
Anti-apoptotic 
Inhibits apoptosis 
 
[164] 
 
ICP27 
 
Multifunctional regulatory protein 
Pro and anti-apoptotic 
Inhibits apoptosis by NFkB 
JNk- Bcl-2- Bax-Bid 
 
[163] 
 
ICP 22 
 
Regulator of viral gene expression 
Promote and Inhibits apoptosis 
Inhibits Caspase 8-9 
AKT- NFkB [165] 
 
ICP0 
 
Anti-apoptotic Inhibits caspase 8 Inhibits apoptosis TNF-a 
 
[164] 
LA
TE
 
 
US3 
(Tegument 
Protein) 
 
Regulates the biological function of 
the virus and the host cells 
Anti-apoptotic 
Inhibits apoptosis phosphorylating 
BAD 
Inhibits Caspase 3 
Bcl2-AKT-BAX-BAD NFkB 
 
[40,163] 
US5 (gJ) 
(Envelope) Anti-apoptotic 
Inhibits Fas 
Caspase 3-8 
 
[163] 
 
US6 (gD) 
(Envelope) 
 
Anti-apoptotic Inhibits by Fas-NFkB  
 
[163,164] 
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Table 2: Summary of the principal HSV-1 proteins involved in immunoevasion. 
 
Phase Gene product ORFs Host target  Inhibited host mechanism 
IM
M
ED
IA
TE
 E
AR
LY
 
ICP0 RL2 
MyD88 TLRs signaling/IFN response 
TIRAP TLRs signaling/IFN response 
p65 NF-kB signaling/IFN response 
STING DNA sensor signaling /IFN response 
IFI16 inflammasome 
DNA PK DNA damage response  
ND10 /Sp100 nuclear bodies chromatin epigenetic regulation 
ICP27 UL54 IRF3 TLRs signaling/IFN response 
    STAT1 JAK/STAT signaling/IFN response 
ICP47  US12 TAP   MHC- I antigen presentation 
EA
RL
Y 
/ 
LA
TE
 tegument protein  UL36USP TRAF3 TLRs signaling/IFN response 
 
 
Vhs 
 
 
UL41 
mRNA host 
IRF7 
JAK/STAT signaling 
Viperin 
ZAP 
Tetherin 
host translational arrest 
TLRs signaling/IFN response  
IFN response 
interferon-stimulated genes 
interferon-stimulated genes 
interferon-stimulated genes 
LA
TE
 
US11 US11 
RIG-1 RLRs signaling/IFN response 
MDA5 RLRs signaling/IFN response 
2’5’OAS interferon-stimulated genes  
PKR interferon-stimulated genes  
ICP34.5  RL1 
TBK1 TLRs signaling/IFN response  
Beclin autophagy 
PKR NF-kB signaling/IFN response 
VP16 UL48 IRF3 TLR3 /IFN response 
gC UL44 C3b complement activation  
gE/gI US8/US7 IgG neutralization/Ab dependent cytotoxicity 
gM UL10 Tetherin interferon-stimulated genes 
gB UL27 PERK protein kinase host translational arrest 
ICP8 UL29 Stress granules host translational arrest 
Ser/Thr Protein  
kinase US3  
IRF3 TLRs signaling /IFN response 
TRAF6 TLRs signaling/IFN response 
STING DNA sensor signaling  
For more details, see references 48 and 61. 
 
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
Table 3: Classes of drugs for the treatment of HSV-1 infection and Alzheimer Disease 
 Class of Drugs Effect on HSV-1 Effect on AD 
General effect References
Ch
em
ic
al
 P
ro
du
ct
s 
Aciclic-guanosine 
analogues: 
Acyclovir, Ganciclovir, 
Penciclovir, 
Valaciclovir, 
Famciclovir 
Reduction of 
HSV-1 particles 
Reduction of Aβ, 
decrease of 
P-tau accumulation 
Reduction of disorders of 
the micro-circulation 
Bradycardia and treatment 
of pain 
Bell’s palsy (cranial nerve 
lesion) 
[140-143, 
166,167] 
Pyrophosphate 
analogues: 
Foscarnet 
Reduction of 
HSV-1 particles 
Reduction of Aβ, 
decrease of 
P-tau accumulation 
Alters antidiuretic 
hormone mediated 
transport water and urea 
[140-143] 
Acyclic nucleotide 
analogues: 
Cidofovir, Adefovir 
Reduction of 
HSV-1 particles 
Reduction of Aβ, 
decrease of  
P-tau accumulation 
Inhibits mitochondrial DNA 
synthesis 
Antiproliferative agents 
[140-143, 
168,169] 
N
at
ur
al
 P
ro
du
ct
s 
Phytochemical: 
Flavonoids, Alkaloids, 
Terpenoids and 
phenols 
Anti-viral 
Anti-
inflammatory 
Protective role in 
nervous system 
disorders 
Anti-inflammatory 
Anti cancer [145] 
Flavonoids: 
Flavanols, flavones, 
Flavonols, isoflavones, 
anthocyanidins 
Anti-viral 
Anti-oxidant 
Cross BBB
Neuropharmacological 
activities 
Influencing protein 
fusion and gene 
expression 
Anti-oxidant 
Anti cancer 
Antiangiogenic 
[145] 
Isoflavones: 
Genistein, Daidzein 
Molecular 
pathways 
altered during 
HSV-1 infection 
Neuroprotective 
agent, antagonizing 
the action of 
estrogens 
Osteogenic function [146] 
Flavones: 
Luteolin, Apigenin, 
Acacetin 
Anti-
inflammatory 
Anti-oxidative 
Anti-viral 
Inhibit the activation 
of proinflammatory 
cytokines, 
Protection AD 
neurons 
Anti-inflammatory 
Anti-oxidative 
 
[147,148] 
Flavanols: 
Epigallocatechin(EGCG) 
Molecular 
pathways 
altered during 
HSV-1 infection 
Prevent neuronal cell 
death Cardiovascular function [149,170] 
Anthocyanidin: 
Cyanidin-3-glucoside 
(C3G) 
Molecular 
pathways 
altered during 
HSV-1 infection 
Neutralize the level of 
Aβ 1-42 
peptides 
Renal protective effect [150,171] 
Flavonols: 
Quercitin 
 
 
Polyphenol: 
Resveratrol 
Sirt1 and AMPK 
pathways 
modulated by 
HSV-1 
Anti-viral effects 
Neuroprotective 
effects, block 
accumulation of Aβ 
peptides in vitro, 
mediate the cleavage 
of APP 
Anti-inflammatory 
Anti-oxidative 
Anti- apoptotic 
 
[152-156, 
158] 
Endogenous fatty acid 
amide (class of nuclear 
factor agonists): 
Palmitoylethanolamide 
(PEA) 
Anti-
Inflammatory 
Neuroprotective 
effects Neurophatic pain [159] 
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